NEW YORK (GenomeWeb News) – Danaher said today that its revenues in the fourth quarter rose 6 percent year over year with its Life Sciences & Diagnostics segment leading the way.

For the three months ended Dec. 31, 2013, the company posted revenues of $5.27 billion, up from $4.98 billion in Q4 2012, and beating the consensus Wall Street estimate of $5.20 billion.

Danaher's profit for the quarter was up to $789.3 million, or $1.11 per share, from $630.4 million, or $0.89 per share, in Q4 2012, besting analyst estimates of $0.95 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.